Login
$HTFL
$47.68 +$0.82 (1.75%) After hours

$HTFL 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

SAN FRANCISCO — November 12, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today reported financial results for the third quarter ended September...

13 Aug 2026 8-K: Results of Operations and Financial Condition

SAN FRANCISCO — August 13, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026.

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The 2026 Annual Meeting of Stockholders (the “Meeting”) of Heartflow, Inc. (the “Company”) was held on June 16, 2026. At the Meeting, the Company’s stockholders voted on the following two proposals and cast their votes as described below.

14 May 2026 8-K: Results of Operations and Financial Condition

SAN FRANCISCO — May 14, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026.

18 Mar 2026 8-K: Results of Operations and Financial Condition

MOUNTAIN VIEW, Calif. – March 18, 2026 – Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, ...

12 Jan 2026 8-K: Regulation FD Disclosure

Disclaimers Forward-Looking Statements This presentation includes express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. ...

12 Nov 2025 8-K: Results of Operations and Financial Condition

Initiates Full Year 2025 Revenue Guidance of $173.0 Million to $173.5 Million

10 Sep 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

As previously disclosed, Heartflow, Inc. (the “Company”) will participate at the Morgan Stanley 23rd Annual Global Healthcare Conference today, September 10, 2025. In connection with meetings with investors at the conference, the Company...

25 Aug 2025 8-K: Termination of a Material Definitive Agreement

On August 22, 2025, Heartflow, Inc. (the “Company”) prepaid in full all outstanding amounts, comprising an aggregate principal amount of $60.1 million plus accrued interest of $1.0 million, under that certain Credit Agreement and Guarant...

11 Aug 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be as set forth in the Certificate of Incorporation of the Corporation (as amended and/or restated from time to time, the “Certif...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support